Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alexion
Biotech
AstraZeneca inks $800M buyout to snag phase 3 rare disease drug
AstraZeneca is paying $800 million to expand into rare endocrinology, snagging itself a phase 3 drug through the acquisition of French biotech Amolyt.
Nick Paul Taylor
Mar 14, 2024 9:47am
SpringWorks eyes AstraZeneca's Koselugo market with phase 2 data
Nov 16, 2023 10:59am
Voyager asset lands on planet Alexion after Pfizer handoff
Nov 6, 2023 4:01pm
Novartis’ iptacopan has ‘faultless’ performance in phase 3
Oct 2, 2023 11:09am
AstraZeneca converges with Verge's AI tech in $42M R&D pact
Sep 8, 2023 7:00am
AstraZeneca axes assets, inks Pfizer deal and loses key R&D exec
Jul 28, 2023 6:00am